Program Description
The recent approvals of additional HER2-targeted agents for treatment of metastatic breast cancer have contributed to improved outcomes for patients with HER2-positive disease, but have also complicated treatment selection. To provide appropriate access and cost-effective use of HER2-targeted treatments, managed care professionals need to be familiar with the clinical data and indications for the use of these agents. In this panel discussion, managed care experts will differentiate among available and emerging agents, as well as detail how these agents fit within guideline recommendations to support optimal treatment sequencing. Panelists will discuss and debate considerations for choosing among guideline-recommended therapies and the impact of later lines of therapy on patient outcomes. Managed care professionals will incorporate strategies to overcome barriers and optimize treatment approaches to ensure cost-effective, outcomes-based, concordant treatment for patients with HER2-positive metastatic breast cancer.
Target audience: Oncology and managed care pharmacists
Type of activity: Application
Release date: August 30, 2024
Expiration date: August 30, 2025
Time to complete activity: 1.5 hours
Learner level: Foundational, Intermediate
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine the current treatment landscape and guideline recommendations for the use of HER2-targeted therapies in the treatment of HER2-positive metastatic breast cancer (MBC)
- Analyze the recent clinical trial data assessing novel therapies and combinations targeting HER2-positive MBC and their potential clinical impact
- Explore the operational and managed care impact of new and emerging data in HER2-positive MBC treatment, including formulary, pathways, resources, cost, and patient outcomes
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
